Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S249000, C514S258100, C514S275000, C514S278000, C514S299000, C514S388000, C514S398000, C514S399000, C514S471000, C514S472000, C514S601000, C514S602000, C514S605000, C544S230000, C544S235000, C544S253000, C544S316000, C544S332000, C544S335000, C544S349000, C546S018000, C546S112000, C546S304000, C546S314000, C548S333100, C548S335500, C549S480000, C549S492000, C564S080000, C564S092000
Reexamination Certificate
active
06849634
ABSTRACT:
Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.
REFERENCES:
patent: 2298443 (1942-10-01), Weissberger
patent: 4422871 (1983-12-01), Schirmer et al.
patent: 4975453 (1990-12-01), Becker et al.
patent: 5006512 (1991-04-01), Ohnishi
patent: 5215985 (1993-06-01), Murphy et al.
patent: 5234947 (1993-08-01), Cherksey
patent: 5242947 (1993-09-01), Cherksey et al.
patent: 5310932 (1994-05-01), Atwal et al.
patent: 5328830 (1994-07-01), Janis et al.
patent: 5356775 (1994-10-01), Hebert et al.
patent: 5401758 (1995-03-01), Atwal et al.
patent: 5401848 (1995-03-01), Atwal
patent: 5451580 (1995-09-01), Murphy et al.
patent: 5453421 (1995-09-01), Atwal et al.
patent: 5486515 (1996-01-01), Brown et al.
patent: 6015822 (2000-01-01), Brendel et al.
patent: 6083986 (2000-07-01), Castle et al.
patent: 6333337 (2001-12-01), Gross et al.
patent: 0 286 278 (1988-10-01), None
patent: 0 317 321 (1989-05-01), None
patent: 0 321 175 (1989-08-01), None
patent: 0 472 053 (1992-02-01), None
patent: 0 488 616 (1992-06-01), None
patent: 0 587 180 (1994-03-01), None
patent: 0 608 858 (1994-08-01), None
patent: 0915087 (1999-05-01), None
patent: 9518617 (1995-07-01), None
patent: 9526342 (1995-10-01), None
patent: WO 9621640 (1996-07-01), None
patent: WO 9636596 (1996-11-01), None
patent: 9725983 (1997-07-01), None
patent: 9726300 (1997-07-01), None
patent: WO 9804521 (1998-02-01), None
patent: 9937607 (1999-07-01), None
patent: WO 0012077 (2000-09-01), None
patent: WO 0146155 (2001-06-01), None
Still, et al., “Rapid Chromatographic Technique for Preparative Separation with Moderate Resolution,” J. Org. Chem., vol. 43, No. 14, 1978, 2923-2925.
Castle, et al., “Characterization of 4-Aminopyridne Block of the Transient Outward K+Current in Adult Rat Ventricular Myocytes,” The Journal of Pharmacology and Experimental, vol. 264, No. 3, 1450-1459 (1993).
Deal, et al., “Molecular Physiology of Cardiac Potassium Channels,” Physiological Reviews, vol. 76, No. 1, Jan. 1996, 49-67.
Wang, et al., “Sustained Depolarization-Induced Outward Current in Human Atrial Myocytes, Evidence for a Novel Delayed Rectified K+Current Similar to Kv1.5 Cloned Channel Current,” Circulation Research, vol. 73, No. 6, Dec. 1993, 1061-1076.
Hamill, “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,” Pflüger, Archiv, (1981) 391:85-100.
Fedida, et al., “Identity of a Novel Delayed Rectifier Current From Human Heart with a Cloned K+Channel Current,” Circulation Research, vol. 73, No. 1, Jul. 1993, 210-216.
Chandy, et al., “Voltage-Gated Potassium Channels Are Required For Human T. Lymphocyte Activiation,” J. Exp. Med., vol. 160, Aug. 1984, 369-385.
Sanguinetti, “Modulation of Potassium Channels by Antiarrhythmic and Antihypertensive Drugs,” Hypertension, vol. 19, No. E, Mar. 1992, 228-236.
Lynch, et al., “Therapeutic Potential of Modulating Potassium Currents in the Diseased Myocardium,” The FASEB Journal, vol. 6, Aug. 1992, 2952-2960.
Colatsky, et al., “Channel Specificity in Antiarrhythmic Drug Action,” Circulation, vol. 82, No. 6, Dec. 1990-2235-2242.
Halliwell, “K+Channels in the Central Nervous System,” 348-381 (1988).
Amos, et. al. “Differences Between Outward Currents of Human Atrial and Subepicardial Ventricular Myocytes,” Journal of Physiology, (1986), 491.1, 31-50.
Wang, et al., “Effects of Flecanide, Quinidine, and 4-Aminopyridine on Transient Outward and Ultrarapid Delayed Rectifier Currents in Human Atrial Myocytes,” The Journal of Pharmacology and Experimental Therapeutics, vol. 272, No. 1, 184-196 (1995).
Lin, et al., “Voltage-Gated Potassium Channel Regulate Calcium-dependent Pathways Involved in Human T Lymphocyte Activation,” J. Exp. Med., vol. 177, 637-645 (1993).
Kaczorowki, et al., “Lymphocyte Ion Channels as a Target for Immunosuppression,” Perspective in Drug Discovery and Design 2 (1994) 233-248.
Leonard, et al., “Selective Blockers of Voltage-Gated K+Channels Depolarize Human T Lymphocytes: Mechanism of the Antiproliferative Effect of Charybdotoxin”, vol. 89, 10094-10098, Nov. 1992.
International Search Report dated Jul. 7, 2002.
Gisbert Schneider, et al. “Virtual Screening For Bioactive Molecules by Evolutionary De Novo Desing”, Angewandte Chemie, International Edition (200), 39(22), 4130-4133.
Beaudoin Serge
Gross Michael F.
Reed Aimee D.
Banner & Witcoff , Ltd.
ICAgen
LandOfFree
Potassium channel inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Potassium channel inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potassium channel inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470192